Abivax releases more data from major Phase 3 wins in ulcerative colitis

Abivax fleshed out its big Phase 3 ulcerative colitis victory, presenting new analyses over the weekend of a past readout that sent its stock soaring. It assessed a pooled group of nearly 1,300 patients from ...